trial · primary record
Calderasib
Neoplasm Malignant
| Phase | Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 150 |
| Primary completion | 2032-04-09 |
| Primary endpoint | Objective Response Rate (ORR) |
| Registry ID | NCT07209111 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-02T15:43:30.505Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07209111
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Calderasib · compound